Your browser version is outdated. We recommend that you update your browser to the latest version.

DeNovX is ...

an innovative pharmaceutical technology company that provides platform products that save time and reduce the costs of  pharmaceutical development. Our pharmaceutical technology division is focused on the commercialization of products to accelerate pharmaceutical development while creating new intellectual property (IP) for commercially relevant drugs. Our pharmaceutical products division is advancing the development of a treatment for inflammatory bowel disease.

 

Over 90% of active pharmaceutical ingredients (APIs) are crystalline solids, and our crystal form development technologies reduce the risks associated with controlling the size, shape, and structure of these high value materials while creating new IP to enhance competitive advantage and to extend product life cycles. 

 

Ulcerative colitis (UC) is one of the inflammatory bowel diseases, and it is a life-long disease with no known cure that affects approximately 1.3 million people in Canada, France, Germany, Great Britain, Italy, Japan, and the United States. Currently available therapies are not universally effective in the treatment of UC, and there exists a significant gap in the cost and effectiveness between the first-line therapy and the more costly biologics. We believe that the drug we are developing, DNVX-078, is well situated to fill this gap and to provide a new alternative to patients with mild to moderate ulcerative colitis.

 

 

Think Forward -  to rational crystal form screening, solid form controls, and new therapies for unmet medical needs.